公开(公告)号：BG106395A

公开(公告)日：2002-12-29

申请号：BG10639502

申请日：2002-02-06

Applicant: BASF AG

Inventor： KLING ANDREAS ,  GENESTE HERVE ,  LANGE UDO ,  LAUTERBACH ARNULF ,  GRAEF CLAUDIA I ,  SUBKOWSKI THOMAS ,  HOLZENKAMP UTA ,  MACK HELMUT ,  SADOWSKI JENS ,  HORNBERGER WILFRIED ,  LAUX VOLKER

IPC: A61K31/4402 ,  A61K31/55 ,  A61K31/5513 ,  A61P3/14 ,  A61P5/18 ,  A61P7/02 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P13/12 ,  A61P17/02 ,  A61P17/06 ,  A61P19/00 ,  A61P19/08 ,  A61P19/10 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00 ,  C07D213/74 ,  C07D223/20 ,  C07D243/38 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D495/14 ,  C07D243/00

Abstract: The invention relates to novel compounds to integrin receptors, to the production thereof and their use as medicaments. 14 claims

公开(公告)号：TR200200357T2

公开(公告)日：2002-09-23

申请号：TR200200357

申请日：2000-08-01

Applicant: BASF AG

Inventor： KLING ANDREAS ,  GENESTE HERV ,  LANGE UDO ,  LAUTERBACH ARNULF ,  GRAEF CLAUDIA ISABELLA ,  SUBSKOWSKI THOMAS ,  HOLZENKAMP UTA ,  MACK HELMUT ,  SADOWSKI JENS ,  HORNBERGER WILFRIED ,  LAUX VOLKER

IPC: A61K31/4402 ,  A61K31/55 ,  A61K31/5513 ,  A61P3/14 ,  A61P5/18 ,  A61P7/02 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P13/12 ,  A61P17/02 ,  A61P17/06 ,  A61P19/00 ,  A61P19/08 ,  A61P19/10 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00 ,  C07D213/74 ,  C07D223/20 ,  C07D243/38 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D495/14

Abstract: The invention relates to novel compounds which bind to integrin receptors, and to the preparation thereof and the use thereof as drugs.

公开(公告)号：NO312674B1

公开(公告)日：2002-06-17

申请号：NO991079

申请日：1999-03-04

Applicant: BASF AG

Inventor： AMBERG WILHELM ,  JANSEN ROLF ,  KLING ANDREAS ,  KLINGE DAGMAR ,  RIECHERS HARTMUT ,  HERGENROEDER STEFAN ,  RASCHACK MANFRED ,  UNGER LILIANE

IPC: A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61P9/04 ,  A61P9/08 ,  A61P9/12 ,  A61P43/00 ,  C07C59/66 ,  C07C69/734 ,  C07D239/34 ,  C07D239/52 ,  C07D239/60 ,  C07D239/70 ,  C07D491/04 ,  C07D491/048 ,  C07D237/34

Abstract: The invention relates to carboxylic acid derivatives of the formula Iwhere the radicals have the meanings stated in the description, and to their use as drugs.

公开(公告)号：CZ20013846A3

公开(公告)日：2002-06-12

申请号：CZ20013846

申请日：2000-04-17

Applicant: BASF AG

Inventor： KLING ANDREAS ,  LANGE UDO ,  LAUTERBACH ARNULF ,  GENESTE HERVE ,  SUBKOWSKI THOMAS ,  ZECHEL JOHANN-CHRISTIAN ,  GRAFF CLAUDIA ISABELLA ,  HORNBERGER WILFRIED

IPC: C12N9/99 ,  A61K31/27 ,  A61K31/381 ,  A61K31/421 ,  A61K31/426 ,  A61K31/4406 ,  A61K31/443 ,  A61K31/4439 ,  A61K38/00 ,  A61K45/00 ,  A61K45/06 ,  A61P3/10 ,  A61P3/14 ,  A61P7/02 ,  A61P9/00 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  A61P13/12 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P43/00 ,  C07C275/42 ,  C07D207/34 ,  C07D213/56 ,  C07D249/14 ,  C07D263/34 ,  C07D263/48 ,  C07D277/20 ,  C07D277/48 ,  C07D277/56 ,  C07D307/68 ,  C07D333/38 ,  C07D333/40 ,  C07D401/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07K5/02 ,  C07K5/023 ,  A61K38/04 ,  A61K31/33

Abstract: The invention relates to new compounds which bind to integrin receptors, as well as to their production, their use as integrin receptor antagonists and for the treatment of diseases, pharmaceutical preparations containing said compounds and pharmaceutical preparations containing at least one other active compound.

公开(公告)号：BR0010092A

公开(公告)日：2002-06-11

申请号：BR0010092

申请日：2000-04-17

Applicant: BASF AG

Inventor： ZECHEL JOHANN-CHRISTIAN ,  KLING ANDREAS ,  GENESTE HERVE ,  LANGE UDO ,  LAUTERBACH ARNULF ,  GRAEF CLAUDIA ISABELLA ,  SUBKOWSKI THOMAS ,  HORNBERGER WILFRIED

IPC: C12N9/99 ,  A61K31/27 ,  A61K31/381 ,  A61K31/421 ,  A61K31/426 ,  A61K31/4406 ,  A61K31/443 ,  A61K31/4439 ,  A61K38/00 ,  A61K45/00 ,  A61K45/06 ,  A61P3/10 ,  A61P3/14 ,  A61P7/02 ,  A61P9/00 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  A61P13/12 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P43/00 ,  C07C275/42 ,  C07D207/34 ,  C07D213/56 ,  C07D249/14 ,  C07D263/34 ,  C07D263/48 ,  C07D277/20 ,  C07D277/48 ,  C07D277/56 ,  C07D307/68 ,  C07D333/38 ,  C07D333/40 ,  C07D401/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07K5/02 ,  C07K5/023 ,  A61K38/04 ,  A61K31/33

Abstract: The invention relates to new compounds which bind to integrin receptors, as well as to their production, their use as integrin receptor antagonists and for the treatment of diseases, pharmaceutical preparations containing said compounds and pharmaceutical preparations containing at least one other active compound.

公开(公告)号：NO20020644A

公开(公告)日：2002-03-18

申请号：NO20020644

申请日：2002-02-08

Applicant: BASF AG

Inventor： KLING ANDREAS ,  GENESTE HERVE ,  LANGE UDO ,  LAUTERBACH ARNULF ,  GRAEF CLAUDIA ISABELLA ,  SUBKOWSKI THOMAS ,  HOLZENKAMP UTA ,  MACK HELMUT ,  SADOWSKI JENS ,  HORNBERGER WILFRIED ,  LAUX VOLKER

IPC: A61K31/4402 ,  A61K31/55 ,  A61K31/5513 ,  A61P3/14 ,  A61P5/18 ,  A61P7/02 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P13/12 ,  A61P17/02 ,  A61P17/06 ,  A61P19/00 ,  A61P19/08 ,  A61P19/10 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00 ,  C07D213/74 ,  C07D223/20 ,  C07D243/38 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D495/14 ,  C07D

CPC classification number: C07D401/06 ,  C07D223/20 ,  C07D243/38 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D495/14

公开(公告)号：NZ502319A

公开(公告)日：2002-03-01

申请号：NZ50231998

申请日：1998-06-05

Applicant: BASF AG

Inventor： AMBERG WILHELM ,  KLING ANDREAS ,  KLINGE DAGMAR ,  RIECHERS HARTMUT ,  HERGENRODER STEFAN ,  RASCHACK MANFRED ,  UNGER LILIANE

IPC: C07D251/16 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/505 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61P7/02 ,  A61P9/02 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P13/08 ,  A61P13/12 ,  A61P25/06 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00 ,  C07C247/12 ,  C07D213/68 ,  C07D237/14 ,  C07D237/16 ,  C07D239/34 ,  C07D239/52 ,  C07D239/56 ,  C07D239/60 ,  C07D239/70 ,  C07D239/80 ,  C07D239/95 ,  C07D241/18 ,  C07D251/22 ,  C07D251/34 ,  C07D251/52 ,  C07D253/06 ,  C07D403/12 ,  C07D491/048 ,  C07C235/12 ,  C07C233/63 ,  C07C229/22 ,  C07C233/47 ,  C07C235/34

Abstract: An b-amino or b-azido carboxylic acid derivative has the formula (I) wherein: R1 is tetrazole or -C(=O)-R; R is OR4, -O-(CH2)p-S(O)k-R5, a 5 membered heteroaromatic system linked via a nitrogen atom, -NH-SO2-R5; A is NR7R8 or azido; W and Z are independently nitrogen or methine provided that Q is nitrogen if W and Z are methine; X is nitrogen or CR9; Y is nitrogen or CR10; Q is nitrogen or CR11 provided that if X is CR9 and Y is CR10 if Q is nitrogen; R2 and R3 are independently optionally substituted phenyl or naphthyl or phenyl or naphthyl is linked together in ortho position by a direct linkage, methylene, ethylene or ethenylene, oxygen, sulphur, SO2, NH or N-alkyl; R4 is H, alkali metal cation, alkaline earth metal cation, or a physiologically tolerated organic ammonium ion, optionally substituted cycloalkyl, alkyl or -CH2-phenyl. k is 0 to 2 and p is 1 to 4; R5 is alkyl, cycloalkyl, alkenyl, alkynyl or optionally substituted phenyl and R7 to R11 are defined in the specification. A pharmaceutical composition thereof is useful as an endothelin receptor antagonist. A compound of formula (II) A-C(R2)(R3)-CH(R1)-OH wherein A and R1 to R3 are as defined above s useful as a starting material to prepare the compounds of formula (I).

公开(公告)号：SI9520061B

公开(公告)日：2002-02-28

申请号：SI9520061

申请日：1995-04-26

Applicant: BASF AG

Inventor： AMBERG WILHELM ,  BERNARD HARALD ,  BUSCHMANN ERNST ,  HAUPT ANDREAS ,  JANITSCHKE LOTHAR ,  JANSSEN BERND ,  KARL ULRICH ,  KLING ANDREAS ,  MUELLER STEFAN ,  DE POTZOLLI BERND ,  RITTER KURT ,  THYES MARCO ,  ZIERKE THOMAS

IPC: A61K38/08 ,  A61K38/00 ,  A61P35/00 ,  C07K1/08 ,  C07K5/10 ,  C07K5/103 ,  C07K7/06 ,  C07K14/52

Abstract: PCT No. PCT/EP95/01577 Sec. 371 Date Nov. 4, 1996 Sec. 102(e) Date Nov. 4, 1996 PCT Filed Apr. 26, 1995 PCT Pub. No. WO95/30691 PCT Pub. Date Nov. 16, 1995The compound Me2Val-Val-MeVal-Pro-Pro-NHBzlxHCl is described. It is prepared from Z-Val-Val-MeVal-Pro-OR1 where Z and R1 have the meanings stated in the description. The compound shows antineoplastic activity.

公开(公告)号：HU0103560A2

公开(公告)日：2002-02-28

申请号：HU0103560

申请日：1999-06-23

Applicant: BASF AG

Inventor： AMBERG WILHELM ,  BARLOZZARI TERESA ,  HAUPT ANDREAS ,  JANSSEN BERND ,  KLING ANDREAS ,  RITTER KURT

IPC: A61K38/00 ,  A61K35/56 ,  A61P35/00 ,  C07K5/103 ,  C07K5/117 ,  C07K7/02

Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula IA-B-D-E-F-G(I)and acid salts thereof, wherein A, D, and E are alpha -amino acid residues, B is an alpha -amino acid residue or an alpha -hydroxy acid residue, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue, and G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a beta -hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sulfoxide or an alkylene sulfone. Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier. An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

公开(公告)号：HU0100957A2

公开(公告)日：2002-02-28

申请号：HU0100957

申请日：1999-02-05

Applicant: BASF AG

Inventor： AMBERG WILHELM ,  HERGENROEDER STEFAN ,  JANSEN ROLF ,  KLING ANDREAS ,  KLINGE DAGMAR ,  RASCHACK MANFRED ,  RIECHERS HARTMUT ,  UNGER LILIANE

IPC: A61K31/505 ,  A61K31/506 ,  A61P5/14 ,  A61P9/02 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P13/12 ,  A61P35/00 ,  A61P43/00 ,  C07D239/34 ,  C07D239/46 ,  C07D239/52 ,  C07D239/60 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

Abstract: The invention relates to carboxylic acid derivatives of formula (I), wherein the substituents have the following meanings; R = tetrazole or a group (1); R = a radical OR (2), (3), a 5-membe red heteroaromatic bonded by a nitrogen atom such a pyrrolyl, pyrazolyl, imidazolyl and trizolyl; R , R = hydrogen, hydroxy, NH2, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, halogen, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkinyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, C1-C4-halogen alkyl, C1-C4-alkoxy, C1-C4-halogen alkoxy or C1-C4-alkythio; X = halogen, C1-C4-halogen alkyl, hydroxy; R and R = phenyl or naphthyl, C3-C7-cycloalkyl, phenyl or naphthyl which are bonded in ortho position by a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an SO2-NH or an N-alkyl group or a 5-membered or 6-membered heteroaromatic; R = hydrogen, phenyl or naphthyl, a five or six-membered heteroaromatic, C1-C8-alkyl, C3-C6-alkenyl, C3-C6-alkinyl or C3-C8-cycloalkyl, whereby said radicals can be substituted once or many times, with the proviso that R can only stand for hydrogen if Z does not represent a single bond; Z = sulfur, oxygen or a single bond, in addition to the physiologically compatible salts and the enantiomeric-pure and diastereomeric-pure forms. The novel compounds are suitable for combating diseases, especially as endothelin antagonists.